TICKERNERD
Menu
ASMBASMBHealthcare · Biotechnology

ASMB Stock Forecast: Assembly Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$30
−2.17% on the day

The 5 Wall Street analysts covering Assembly Biosciences, Inc. hold a median 12-month price target of $52 — +74.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$606.6M
Ticker Nerd rank
89 / 100
Median analyst target
$52
Analysts covering
5
Revenue$13.4M+38.9% y/y
Operating income−$6.3M
Net income−$3.9M
Free cash flow−$15.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.5%
1M
+9.3%
YTD
−12.4%
1Y
+31.9%
From 52W high
−22.6%
From 52W low
+45.0%
$21
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ASMB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Assembly Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Quality
90
Volatility
90
Value
90
Revisions
82
Momentum
72
Size
51
Issuance
30
Accruals
10

Growth (92): Sales and profits are climbing, and climbing faster than before.

Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ASMB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASMB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26ASMBHigh $62Median $52Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $43Median $52High $62

The green dot is the last close — the median target sits +74.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Sept 2026MizuhoMaintainsOutperform$53 → $45
1 Sept 2026UBSInitiatesBuy$52
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
18 Aug 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026MizuhoMaintainsOutperform—
15 June 2026MizuhoMaintainsOutperform$40 → $45
28 May 2026GuggenheimReiteratesBuy—
4 May 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026GuggenheimMaintainsBuy—
26 Mar 2026HC Wainwright & Co.ReiteratesBuy—
22 Dec 2025HC Wainwright & Co.ReiteratesBuy—
20 Nov 2025MizuhoMaintainsOutperform—
14 Oct 2025HC Wainwright & Co.ReiteratesBuy—
24 Sept 2025JMP SecuritiesInitiatesMarket Outperform—
8 Sept 2025GuggenheimMaintainsBuy—
18 Aug 2025HC Wainwright & Co.AssumesBuy$50
25 Mar 2025GuggenheimInitiatesBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
27 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
24 Sept 2024HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ASMB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ASMB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Assembly Biosciences, Inc. returned +31.9% against +17.5% for the S&P 500, dividends included.

ASMB vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Oct 25Jan 26Apr 26Jul 26ASMBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ASMB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−184.1%
Analysts raising
2
Analysts cutting
0
Fundamentals

Assembly Biosciences, Inc. (ASMB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.0×

Cheaper than 31% of US stocks

Price / sales
8.1×

Cheaper than 16% of US stocks

Price / book
1.9×

Cheaper than 47% of US stocks

EV / EBITDA
−33.2×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
38.9%

Higher than 82% of US stocks

Earnings growth (YoY)
38.9%

Higher than 71% of US stocks

Gross margin
—
Operating margin
−47.4%

Higher than 17% of US stocks

Net margin
−0.1%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−0.0%

Higher than 44% of US stocks

Return on assets
−2.7%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Assembly Biosciences, Inc. (ASMB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Assembly Biosciences, Inc. has a market value of $606.6M and an enterprise value of $288.7M.

  • Revenue in the twelve months to 30 June 2026: $74.8M. The latest quarter grew 38.9% year on year.

  • Net income over the same four quarters: −$42K, a −0.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$38.6M.

  • Shares outstanding: 19.9M.

  • Trailing P/E: 24.0×; forward P/E: −11.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Assembly Biosciences, Inc. employs 73 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

ASMB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ASMBAssembly Biosciences, Inc.$606.6M
89
ALLOAllogene Therapeutics, Inc.$589.7M
78
OABIOmniAb, Inc.$591.7M
95
CTNMContineum Therapeutics, Inc.$574.4M
59
CRMDCorMedix, Inc.$613.0M
60
PRMEPrime Medicine, Inc.$567.7M
36
DRUGBright Minds Biosciences, Inc.$614.9M
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Assembly Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ASMB news & analysis

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

Assembly Biosciences announced that its senior management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. The company develops therapeutics targeting serious viral and liver diseases.

Why it matters — The presentation gives ASMB watchers an opportunity to hear directly from senior management about the company at a major investment conference.

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

Zacks Investment Research · 9 Sept 2026positive

Zacks Investment Research identified ASMB as one of four defensive picks amid market volatility driven by rising oil prices and escalating Middle East tensions. The report highlights these stocks as relatively resilient choices during the current period of uncertainty.

Why it matters — ASMB was singled out as a defensive pick, which could draw positive attention from investors seeking stability in a volatile market environment.

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

GlobeNewsWire · 8 Sept 2026neutral

Assembly Biosciences has exercised its U.S. profit-share option with Gilead for its helicase-primase inhibitor program targeting recurrent genital herpes. Under the agreement, Assembly Bio will share 40% of U.S. development costs and profits for the program.

Why it matters — This update confirms the financial structure of Assembly Biosciences' collaboration with Gilead on a key clinical program, informing investors about the company's cost-sharing and profit-sharing position in the U.S. market.

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

Zacks Investment Research · 7 Sept 2026positive

Wall Street analysts' average price target for Assembly Biosciences (ASMB) suggests a potential upside of about 35.7%. The article notes that while the reliability of this metric is questionable, a positive trend in earnings estimate revisions may support further upside in the stock.

Why it matters — ASMB watchers would care because analyst price targets and positive earnings estimate revisions signal how Wall Street currently views the stock's prospects.

Should You Buy Assembly Biosciences (ASMB) After Golden Cross?

Zacks Investment Research · 4 Sept 2026positive

Zacks Investment Research reported that Assembly Biosciences (ASMB) reached a significant support level, and its 50-day simple moving average crossed above its 200-day moving average, forming a technical pattern known as a "golden cross." The report notes this could make ASMB a good pick from a technical perspective.

Why it matters — ASMB watchers would care because the golden cross is a widely followed technical signal that indicates a potential shift in the stock's price momentum.

FAQ

Frequently asked questions about ASMB stock

What is the ASMB stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Assembly Biosciences, Inc. have a median 12-month price target of $52, with estimates ranging from $43 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ASMB stock a buy right now?

Of the 5 analysts covering Assembly Biosciences, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Assembly Biosciences, Inc. 89 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ASMB?

As at 12 Sept 2026, Assembly Biosciences, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

Will ASMB stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +74.5% from the last close, and Ticker Nerd's factor model ranks Assembly Biosciences, Inc. 89 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ASMB stock forecast for 2030?

No analyst covering Assembly Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $62 over the next 12 months.

How has ASMB stock performed over the past year?

Assembly Biosciences, Inc. returned +31.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Assembly Biosciences, Inc. do?

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases.

What is the latest news on ASMB?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference". Assembly Biosciences announced that its senior management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. The company develops therapeutics targeting serious viral and liver diseases.

Company

About Assembly Biosciences, Inc.

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatitis B virus, hepatitis D virus, and other infectious conditions, with programs designed to target key stages of viral replication and disease progression. The company also advances research in related areas such as cholestatic liver disease and microbiome-linked disorders through orally delivered therapeutic candidates. Assembly Biosciences Inc. works across discovery, preclinical, and clinical development, positioning itself within the infectious disease and liver disease segments of the biotechnology market. Headquartered in South San Francisco, California, the company concentrates on creating novel treatment approaches intended to address unmet medical needs in virology and liver health.

CEO Mr. Jason A. Okazaki J.D. · 73 employees · United States · https://www.assemblybio.com